New cancer drug KK2269 enters first human tests
NCT ID NCT06266299
First seen Feb 01, 2026 · Last updated Jun 23, 2026 · Updated 25 times
Summary
This early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 alone, then testing it with docetaxel in specific cancer types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aichi Cancer Center
RECRUITINGNagoya, Aichi-ken, 464-8681, Japan
-
Cancer Institute Hospital of JFCR
RECRUITINGKoto-Ku, Tokyo, 135-8550, Japan
-
City Of Hope National Medical Center
RECRUITINGDuarte, California, 91010, United States
-
Hoag Memorial Hospital Presbyterian
RECRUITINGNewport Beach, California, 92663, United States
-
Mayo Clinic Arizona
RECRUITINGScottsdale, Arizona, 85259, United States
-
Mayo Clinic Jacksonville
RECRUITINGJacksonville, Florida, 32224, United States
-
National Cancer Center Hospital
RECRUITINGChuo-ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
RECRUITINGKashiwa, Chiba, 277-8577, Japan
-
The University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
-
University of Washington
RECRUITINGSeattle, Washington, 98195, United States
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KK2269 (an experimental drug) and docetaxel (a chemotherapy drug)
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early, first-in-human trial focused on safety, not effectiveness. The drug may not work or could cause serious side effects. It will take years before any potential treatment is available.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.